fibrodysplasia ossificans progressiva
Rare disease · 2024–2024
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| palovarotene Chronic treatment and flare-up treatment of Fibrodysplasia ossificans progressiva (FOP) in patients aged ≥8 years (females) or ≥10 years (males). | Nov 2024 | Recommended with restriction | input received FOP Australia |
Who spoke
FOP Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.